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Abstract
Background: The chronic use of antifungal agents in the treatment of fungal infection in general and
oropharyngeal candidiasis mainly in AIDS patient’s leads to the selection of strain resistant to these therapies and a
shift in the spectrum of Candida species. This study determines the species diversity and in vitro susceptibility of
Candida isolates from late presenting AIDS patients in northwest Ethiopia.
Methods: Two hundred and twenty one HIV/AIDS patients were assessed with a standardized evaluation form at
enrolment. Oral rinses were cultured on CHROMagar plates at 37°C for 48 hours and Candida species identification
were made following standard microbiological techniques. In vitro drug susceptibility tests were made using broth
microdilution method.
Results: The colonization rate of Candida species was found to be 82.3% (177/215). C. albicans was the
predominant species isolated from 139 (81%) patients but there was a diversity of other species. C. glabrata was the
most frequent non-albicans species isolated in 22.5% (40/177) of the patients followed by C. tropicalis 14.1% (27/
177), C. krusei 5.6% (10) and other unidentifiable Candida species 4% (7/177). Recurrent episodes of oropharyngeal
candidiasis and previous exposure to antifungal drugs were found to be predisposing factors for colonization by
non-albicans species. Irrespective of the Candida species identified 12.2% (11/90), 7.7% (7/90) and 4.7% (4) of the
isolates were resistant to fluconazole, ketoconazole and itraconazole, respectively. In contrast, resistance to
micafungin, amphotericin B and 5-Fluorocytosine was infrequent.
Conclusion: HIV/AIDS patients are orally colonized by single or multiple albicans and non- albicans Candida species
that are frequently resistant to azoles and occasionally to amphotericin B, 5-Fluorocytosine and micafungin. These
highlight the need for national surveillance for examining Candida epidemiology and resistance to antifungal drugs.
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Background
Candida species are among the gut flora, the many organ-
isms which live in the human mouth and gastrointestinal
tract. Up to 75% of healthy individuals carry the yeast
Candida as part of their normal commensal oral micro-
flora. However, in the past 3 decades, infections due to
Candida species have increased dramatically and are of
particular importance because of the rising number of
immunocompromised patients [1]. Oropharyngeal candid-
iasis (OPC) is one of Candidal infection which continues
to be a common opportunistic infection in patients infected
by the human immunodeficiency virus (HIV). It increase
morbidity and mortality and reduces length and quality of
life of HIV/AIDS patients. It occurs in up to 90% of the
patients at some point during the course of HIV disease
and is associated with high viral loads, low CD4+ T cell
count (< 200 cells/mm3) and disease progression [1-4]. The
prolonged course of HIV infection predisposes these
patients to recurrent episodes of OPC that can increase in
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frequency and severity with progressive HIV disease [5].
Today although, the introduction of highly active anti-
retroviral therapy (HAART) has dramatically reduced the
incidence of opportunistic infections among HIV-positive
people who have received the drugs, OPC with a shift
in the spectrum of Candida species remains the most
frequent HIV-associated oral lesion in most developing
countries, including Ethiopia [2,5], where access to
HAART is still limited.
The high incidence of mucosal and deep seated forms of
candidiasis has resulted in the use of systemic antifungal
agents, especially fluconazole and itraconazole [6]. The
widespread these antifungal agents have been followed by
an increase in antifungal resistance and by a noticeable
shift toward non albicans species with relative resistance
to fluconazole and itraconazole [7] and there have been
reports of emergence of resistance to antifungal agents in
HIV/AIDS patients with OPC [8-13]. Certain non-albi-
cans species, for example C. glabrata and C. krusei are in-
herently less susceptible to fluconazole than C. albicans
and have been isolated with increasing frequency in HIV-
infected patients [14]. The resistance of Candida isolates
to currently available antifungal drugs is a highly relevant
factor because it causes important implications for mor-
bidity and mortality.
Like other African countries, the present guideline of
the Ethiopian Ministry of Health (MOH) for the manage-
ment of candidiasis include fluconazole, as a first choice
drug and ketoconazole, micoconzole ointment as alterna-
tive antifungal agents. However, clotrimazole oral torches,
nystain oral suspension, genital violet solution and 2%
sodium benzoate solution are also prescribed in routine
clinical practice [15,16]. In Ethiopia, fungal culture and
in vitro antifungal testing are not performed in routine
clinical laboratory practice and data on the circulating
Candida species and antifungal drug resistance are inad-
equate except for a single study conducted over a decade
[13]. Recently, we have reported Candida species diversity
and found fluconazole resistance strains of Candida spe-
cies among 13 AIDS patients with advanced diseases from
central Ethiopia [9,17]. These initiated us to conduct a
large scale study in tropical settings of northwest Ethiopia
where HIV/AIDS patients present late in the course of the
diseases and OPC is observed as a major AIDS defining
event. The objective of this study was therefore, to deter-
mine the diversity of Candida species and in vitro suscep-
tibility of Candida species isolated from AIDS patients to
six common antifungal agents.
Methods
Settings
Ethiopia is a low income country with an estimated HIV
prevalence of 2.1% in 2009 [18] and where OPC remains
the most frequent HIV associated oral lesion. Gondar
University teaching hospital is a tertiary level referral
and teaching hospital in northwest Ethiopia rendering
health service for over 5 million inhabitants. Northwest
Ethiopia, the area where the study was conducted, is a
high HIV prevalence region with almost all HIV in-
fections occurs through the heterosexual route. The
Gondar University teaching hospital HIV clinic consists
of an Integrated Counselling and Testing Centre, in ad-
dition to a CD4+ T cells monitoring laboratory and ART
pharmacy. HIV treatment and monitoring is free of cost.
Patients
Two hundred and twenty one consecutive patients were
recruited at the University of Gondar teaching Hospital
HIV clinic from April 2008-November 2008 when they
were referred to the clinic from voluntary HIV counsel-
ling and testing (VCT) centre and/or from out patients
departments (OPD) and/or other health institutions.
Patients were eligible for the study if they were HIV-
positive, greater than 18 years of age and willing to par-
ticipate in the study. All the patients were antiretroviral
naïve with various WHO clinical stages. Patients were
assessed with a standardized evaluation form at enrol-
ment where sociodemographic data and clinical findings
were recorded. Patients were interviewed to determine
the previous episodes of OPC and use of antifungal
agents. Primary OPC was defined as the one that occur
for the first time and recurrent OPC as the second epi-
sode and above during the course of HIV disease. Ap-
parently healthy HIV negative blood donors (free from
blood borne infection, chronic illness and acute infec-
tions) were also included and served as a control.
CD4+ T cell counts
Blood was collected in EDTA tubes from each patient for
enumeration of CD4+ and CD8+ T cells using a fluores-
cent activated cell sorter (FACS) count machine (Becton
Dickinson, San Jose, California, USA) following the manu-
facturer’s protocol. According to the first CD4+ T cells
count before HAART, patients were classified as early
presenter (CD4+ T cells > 200 cells/μl) and late presenter
(CD4+ T cells <200 cell/μl). The Federal HIV/AIDS treat-
ment guideline do not include a formal definition of late
presentation, but has been strongly recommend that any
patients with CD4+ T cells count of < 200 cells/μl irrespect-
ive of WHO clinical stage should receive treatment during
the study period [16].
Isolation and identification of Candida species
After informed and written consent was obtained, the
study subjects were instructed to provide rinse of oral
cavity as we have previously described elsewhere [9,17].
Briefly, oral rinses were obtained from each subject by
asking them to rinse their mouth with 5 ml of sterile
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normal saline (0.85% NaCl solution) for 30 seconds and
to expectorate the rinse into a sterile container. The
mixture was then thoroughly mixed for homogenization
and 0.1 ml of the fluid was then, plated to a CHROMagar
plate (CHROMagar, Paris, France), a selective medium for
isolation of Candida species which was prepared as per
the manufacturer’s instruction. After 60 seconds, the
plates were drained and incubated at 37°C for 48 hours.
Presumptive identification of Candida was made based on
color of the colonies as per the protocol of the ma-
nufacturer as C. albicans, C. tropicalis and C. glabrata.
Colonies were counted irrespective of single or mixed col-
onies. A cut off point was established for colony counts,
so that 400 or greater CFU/ml was considered a high CFU
count as previously reported [18]. In 25% of the isolates,
further identification of Candida was done using Tobaco
agar which we have previously evaluated using PCR as
gold standard [17]. The isolates were also confirmed by
API 20C AUX identification System for yeasts (Bio-
Merieux, Marcy L’Etoile, France). Isolates were stored at
−40°C with 50% glycerol based Tryptose Soya Broth sup-
plemented with 0.5% yeast extract and cultured on CHRO-
Magar at 37°C prior to being tested for their susceptibility.
In vitro antifungal susceptibility test
The in vitro activities of fluconazole, ketoconazole,
5-Fluorocytosine and amphotericin B (Sigma Aldrich,
Steinheim, Germany), itraconazole (LKT Laboratories,
Inc US) and micafungin (Astellas Pharma, US) were as-
sessed according to CLSI [19] with a slight modification.
Briefly, inoculums suspension was adjusted to a 0.5 McFar-
land Standard to produce 1 × 106 to 5 × 106 cells per ml. A
working suspension was made as by a 1: 100 dilutions. Im-
mediately, 10 μl of this saline suspension was transferred to
10 ml of sterile saline. After the suspension was mixed, it
was poured into an inoculation tray. By use of a 12-channel
pipette and sterile tips, 100 μl of the inoculum was added
to wells 1 to 11 (wells 1 to 10 contained 100 μl a serial two-
fold dilutions of antifungal agents; well 11 was the growth
control without the antifungal); well 12 was the sterility
control or blank) in Tryptose Soya Broth (TSB) a non
synthetic medium supplemented with 0.5% yeast extract.
TSB contains Casein and Soybean Meal-nitrogen sources;
Dextrose-carbon energy source that facilitates organism
growth; Sodium Chloride-maintains osmotic balance; Dipo-
tassium Phosphate-a buffering agent and provides an opti-
mal recovery of C. albicans and C. glabrata [20].
The range of fluconazole concentrations tested was
0.125–64 μg/ml and for itraconazole, ketoconazol, 5-Fuoro-
cytosine and micafungin the range was 0.016–16 μg/ml and
for amphotericin B the range was 0.125–8 μg/ml. This in-
oculum is equivalent to 5.0 × 102 to 2.5 × 103 cells per ml.
The microtiter plate was shaken on a plate shaker for 30
seconds to ensure even distribution of the inoculums. After
incubation at 37°C for 48 hours, the microtiter plate was
taken out from the incubator and shaken for 5 minutes.
The minimum inhibitory concentrations (MICs) were
determined by reading the optical density (OD) of each well
at 530 nm spectrophotometrically. The ODs of the blanks
were subtracted from the ODs of the inoculated plates and
the percentages of growth for each well were calculated.
The MICs of the azoles (fluconazole, itraconazole, ketoco-
nazole) were defined as the lowest concentrations that in-
hibit growth by 50%. Tests were done in duplicate and the
MIC values were the average of the duplicate measurement.
Resistance breakpoint definitions were based on CLSI
guideline [19] and are as follows for azoles: Fluconazole:
resistant ≥ 64 μg/ml, susceptible-dose dependent (S-DD)
16-32 μg/ml and susceptible ≤ 8 μg/ml; itraconazole: re-
sistant ≥ 1 μg/ml, SDD 0.25-0.5 μg/ml and susceptible
≤ 0.125 μg/ml; ketoconazole: resistant ≥ 4 μg/ml. Resist-
ance breakpoint definitions for the fluorinated pyrimi-
dine analogue (5-Fluorocytosine) were also as follows:
susceptible ≤4, SDD 8–16 and resistant >16 μg/ml μg/ml.
There were no CLSI endpoints defined for the polyene
(amphotericin B) and their MICs were defined as the low-
est concentrations that inhibit growth by 100%. However,
in this study we used the values of > 2 μg/ml for resistance
to amphotericin B as endpoints as reported by Brito et al.
[21]. Resistance for the echinocandin antifungal agent
(Micafungin) were defined as the lowest concentrations
that inhibit growth by 50% [19]. Standard strains of
C. albicans ATCC 10231 were used for quality control.
MIC50 and MIC90 are the minimum inhibitory concentra-
tion values that able to inhibit 50% and 90% of the orga-
nism, respectively.
Statistical analysis
The data was computerized in Microsoft Excel and trans-
ferred to SPSS version 17 for analysis. Differences between
continuous variables were assessed by means of two-tailed
Student’s t-test for differences in means and percentages.
Differences between categorical variables were evaluated
by chi square test. P values < 0.05 were considered statisti-
cally significant.
Ethical issues
This study was approved by the University of Gondar
Institutional Review Committee. After the goals and ob-
jectives of the study were explained to the study partici-
pants, informed consent was obtained from each subject.
Results
Patient’s characteristics
Two hundred and twenty one HIV-1 infected patients
(92 males and 128 females) were included in the study.
The mean ± SD age was 32.5 ± 8.5 years (range 16–50
years). The demographic characteristics and baseline clinical
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and immunological data of the patients is summarized in
Table 1. The median CD4+ T cells count among males
(207 cells/μl) and females (213 cells/μl) was not statistically
different. One hundred and twenty five (56.7%) of the
patients were found to be late presenters and the rest 96
(43.3%) were early presenters. Frequency of late presenta-
tion was highest in females and age group >40 years, with
being statistically significant (p < 0.001). More than 65% of
these patients were with advanced AIDS diseases (WHO
clinical stages 3 and 4). In a multivaraint logistic regression
analysis, we found that females were at a significantly
higher risk to present late compared to their male counter-
parts (late presentation: OR 0.49; 95% CI 0.41 – 0.54).
Upon oral examination, 82 (37.5%) had clinical oral cadi-
diasisis with pseudomembraneous candidiasis (43), ery-
thematous candidiasis (33), candida leucoplakia (3) and
angular chielatis (3) types. Of the 82 patients with clinical
OPC, 11 patients were early presenters with CD4+ T cell
count of >200 cells/μl.
Candida species diversity
Of the total 221 patients enrolled in the study, it was
possible to collect oral rinse from 215 patients. The
colonization rate of Candida species was found to be
82.3% (177/215). As expected C. albicans was the most
predominate isolate occurring in 78.5% (139/177) of the
patients either as the single species (99 subjects) or
mixed with other Candida species (40 subjects). C. glab-
rata was the most frequent non-albicans species isolated
in 22.5% (40/177) of the patients followed by C. tropica-
lis 14.1% (27/177), C. krusei 5.6% (10) and other uniden-
tifiable Candida species 4% (7/177). Multiple Candida
species colonization was observed in 42 (23.7%) patients
(Table 2) and the over all species specific isolation was
136, 37, 25, and 10 for C. albicans, C. glabrata, C. tropi-
calis and C. krusei, respectively out of the total 215 oral
rinse samples. Three forth of the patients with multiple
Candida colonization had reported a recurrent episode
of OPC and half of them had previous exposure to
antifungal agents. Candida colonization rate was not
dependent on age, CD4+ T cell count and WHO clinical
stage. The majority (72%) of the patients with clinical
OPC were colonized by C. albicans and the rest by non-
albican Candida species. Among the 36 patients who
have been colonized by non Candida species alone, the
majority (78%) had exposure to common antifungal
agents and had reported previous episodes of OPC. Lim-
ited Candida species diversity was observed among healthy
controls (C. albicans, C. glabrata and C. tropicalis) com-
pared with AIDS patients (C. albicans, C. glabrata, C. tro-
picalis, C. krusei, C. parapsilosis, and C. kefyr).
In vitro antifungal drug susceptibility
In vitro antifungal drug susceptibility test was done on ran-
domly selected isolates of C. albicans (25), C. glabrata (25)
Table 1 Demographic and baseline clinical and























Malnutrition (BMI in kg/m2)
Sever (<15.9) 26 (12.3)
Moderate (16–16.9) 24 (11.4)
Mild (17–18.4) 49 (23.2)
Normal (>18.5) 112 (53.1)
Table 2 Distribution of oral Candida isolates among AIDS
patients, northwest Ethiopia, 2008
Species No (%) Total isolates
Candida albicans 99 (46.0) 137
Candida tropicalis 15 (7.0) 40
Candida glabrata 12 (5.6) 25
Candida krusei 2 (0.009) 10
Candida albicans + Candida glabrata 22(10.2) -
Candida albicans + Candida tropicalis 7(3.2) -
Candida albicans + Candida krusei 7(3.2) -
Candida tropicalis + Candida glabrata 2(0.009) -
C. albicans + C. tropicalis + C. glabrata 1 -
C. albicans + C. krusei + C. tropicalis +
C. glabrata
1 -
Other Candida species* 7 (3.2) 7
*: Unidentified Candida species.
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and unidentified Candida species (5) and for all isolates of
C. tropicalis (25) and C. krusei (10). As shown in Table 3,
irrespective of the Candida species identified 12.2% (11/
90), 3.3% (3/90) and 84.4% (76/90) of the isolates were
resistant, SDD and susceptible to fluconazole. The MICs
value of susceptible Candida isolates (irrespective of the
species) to fluconazole was 7.32 μg/ml with 6.9 μg/ml,
6.1 μg/ml, 8.24 μg/ml and 8.04 μg/ml for C. albicans,
C. tropicalis, C. glabrata and C. krusei, respectively.
Seven of the isolates (7.7%) were found to be resistant
for ketoconazole with a mean ± SD MIC value of 4.92 ±
2.4. Four (4.7%) of the isolates were resistant to itracona-
zole, while 3 (3.3%) were SDD and the remaining 83
(92.2%) of the isolates were found to be susceptible to itra-
conazole. Three (3.5%), 2 (2.3%) and 2 (2.3%) of all the
isolates were found to be resistant to amphotericin B, 5-
Fluorocytosine and micafungin, with relatively low MIC
value of 0.13, 1.26 and 1.28 μg/ml, respectively. Of the 90
Candida isolates tested for in vitro susceptibility, 9 (10.5),
8 (9.4), 6 (7.1), 2 (2.3), 3 (3.5) and 3 (3.5) of the isolates
were found to be resistance for fluconazole, ketoconazole,
itraconazole, micafungin, amphotericin B and 5- Fluorocy-
tosine, respectively (Table 3). Multidrug resistance (resist-
ance to two or more antifungal) strains were also detected
in 8 isolates (3 C. albicans, 2 C. glabrata, 1 C. tropicalis, 1
C. krusei and 1 other Candida species). Thirty one (36%),
5 (5.8%), 2 (2.3%) and 3 (3.5%) of the isolated Candida
species were found to be resistant to one, two, three and
four of the antifungal agents tested, respectively. Four
(16%), 3 (12%) and 18 (72%) of C. albicans isolates were
found to be resistant, SDD and susceptible to fluconazole,
respectively. Only two of the isolated C. glabrata isolates
(8%) was resistant to fluconazole, while 22 (88%) were sus-
ceptible and 1 (4%) were SDD. Similar pattern of suscepti-
bility and resistance was also observed to this agent by C.
tropicalis. All except one C. krusei isolates were suscep-
tible to fluconazole. The susceptibility/resistance profile of
the Candida isolates to other antifungal agents is sum-
marized in Table 4. Moreover, a total of 20 Candida iso-
lates (10 C. albicans, 5 C. glabrata and 5 C. tropicalis)
obtained from HIV negative individuals were also evalu-
ated for antifungal drug susceptibility. A significant differ-
ence on MIC value was observed on all isolates from
healthy controls when compared with MIC value of Can-
dida species isolated from AIDS patients (data not shown).
Cross resistance
From the total of 9 Candida isolates which were resist-
ant to fluconazole, 2 and 5 were concurrently found to
be resistant to ketoconazole and itraconazole, respect-
ively. Three of the ketoconazole resistant isolates were
found to be resistant to fluconazole. There was a significant
difference in frequency of resistance to fluconazole be-
tween the ketoconazole resistant and susceptible Candida
isolates (p < 0.05). Two ketoconazole resistant strains were
resistant to 5-Fluorocytosine. None of azole resistant iso-
lates was found to be resistant to micafungin and ampho-
tericin B.
Risk factors for Candida load and drug resistance
There was no difference on median Candida counts in
men (30 CFU/ml; range, 0 to 48,000 CFU/ml) and women
(600 CFU/ml; range, 0 to 82,000 CFU/ml; p = 0.09) and in
age groups. However, there was a significant relationship
between CD4+ T cell count and Candida CFU counts
(p = 0.0021). Patients with clinical signs of candidiasis
had significantly (p < 0.05) higher Candida counts (12, 346
CFU/ml) compared with patients without clinical candi-
diasis (6783 CFU/ml). On the other hand, there was no
significant difference on Candida count among patients
with and without drug resistant Candida strains (9769 vs.
10, 341 CFU/ml). However, patients colonized by C. albi-
cans had higher CFU than patients colonized by non-albi-
cans (p = 0.03) and multiple colonization was associated
with higher CFU counts (p = 0.001). The difference on
Candida load was significantly low on all isolates from
healthy controls when compared with the Candida load of
Candida species isolated from AIDS patients (2363 CFU/
ml vs 67, 781 CFU/ml; p = 0.0001).
Attempt was made to determine the number of episodes
of OPC and use of antifungal agents. Thirty seven patients
had reported as the second episode of OPC. Forty three
(19.5%) of these patients had previous exposure for either
for systemic (fluconazole) or topical (clotrimaxzole and/
or ketoconazole) antifungal agents. The mean duration of
the antifungal therapy and sampling of oral rinse was 27
days (6–39 days). All ‘azole’ antifungals had higher MIC
value against Candida isolates (irrespective of species) iso-
lated from patients who had been previously exposed to
antifungal compared with those isolated from antifun-
gal naïve patients (fluconazole, p = 0.024; ketoconazole,
p = 0.007; itraconazole, p = 0.004). Similarly, ‘azole’ anti-
fungals tested were less effective against Candida isolates
(irrespective of species) isolated from late presenters
compared with those isolated from early presenters
(fluconazole, p = 0.024; ketoconazole, p = 0.007; itracona-
zole, p = 0.004). No significant differences were observed
(p > 0.005 in all cases) in MICs values of micafungin, 5-
Fluorocytosine and amphotericin B between antifungal
exposed and naïve patients; and between late and early
presenters.
Discussions
The present study is the first study in the era of HAART
among Ethiopian AIDS patients where they present late
in the course of the diseases. The study shows C. albi-
cans as the predominant etiologic agent for OPC among
Ethiopian late and early presenting AIDS patients with
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Table 3 Antifungal susceptibility profile of oral Candida isolates from AIDS patients, northwest Ethiopia, 2008/09
Species/Antifungal agent MIC (μ/ml) SDD R: n (%)
MIC Range MIC50 MIC90
All isolates (90)
Fluconazole 0.125–64 0.25 2 3 (3.3) 11 (12.2)
Ketoconazole 0.016–16 2 4 - 7 (7.7)
Itraconazole 0.016–16 0.016 0.063 3 (3.3) 4 (4.7)
Amphotericin B 0.125– 8 0.125 0.125 - 3 (3.5)
5-Fuorocytosine 0.125–16 0.125 0.125 - 2 (2.3)
Micafungin 0.015–8 0.06 1.2 - 2 (2.3)
C. albicans (25)
Fluconazole 0.125–64 0.25 2 1 (4) 4 (16)
Ketoconazole 0.016–16 - 3 (12)
Itraconazole 0.016–16 0.016 0.063 3 (12) 2 (8)
Amphotericin B 0.125–8 0.5 0.5 - 1 (4)
5-Fuorocytosine 0.125–16 - - - 1 (4)
Micafungin 0.015–8 - - - 1 (4)
C. glabrata (25)
Fluconazole 0.125–64 0.25 2 1 (6) 3 (8)
Ketoconazole 0.016–16 - - - 1 (4)
Itraconazole 0.016–16 0.016 0.063 2 (12) 1 (4)
Amphotericin B 0.125–8 0.5 - - -
5-Fuorocytosine 0.125–16 - - - 1 (4)
Micafungin 0.015–8 - - - -
C. tropicalis (25)
Fluconazole 0.125–64 0.25 2 - 2 (8)
Ketoconazole 0.016–16 - 1 (4)
Itraconazole 0.016–16 0.016 0.063 2 (12) 1 (4)
Amphotericin B 0.125–8 0.5 0.5 - -
5-Fuorocytosine 0.125–16 - - - 1 (4)
Micafungin 0.015–8 - - - -
C. krusei (10)
Fluconazole 0.125–64 0.25 2 1 (10) 1 (10)
Ketoconazole 0.016–16 - - - 1 (10)
Itraconazole 0.016–16 0.016 0.063 1 (10) -
Amphotericin B 0.125–8 0.5 - - -
5-Fuorocytosine 0.125–16 - - - -
Micafungin 0.015–8 - - - -
Other Candida species* (5)
Fluconazole 0.125–64 0.25 2 - 1 (20)
Ketoconazole 0.016–16 - - - 1 (20)
Itraconazole 0.016–16 0.016 0.063 1 (10) -
Amphotericin B 0.125–8 - - - -
5-Fuorocytosine 0.125–16 - - - -
Micafungin 0.015–8 - - - -
*: Unidentified Candida species.
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no significant difference in species distribution between
the two groups of patients (p = 0.344). Although, studies
on diversity of Candida species in Africa in general and
in Ethiopia in particular are limited, few previous studies
conducted so far demonstrated that more than 80% of
oral yeast isolates from HIV-infected patients were of
C. albicans [8,12,13,22-24] which is consistent with our
findings. The distribution of Candida isolates from
patients with recurrent OPC and/or previously exposed
to antifungal drugs in the current study was different
and supports the notion that repeated exposure to anti-
fungal agents and recurrent infections might predispose
to a shift to non-albicans Candida species [7,10] but it
should be supported by further longitudinal studies. This
could be due to the fact that, majority of the patients
(90%) with recurrent OPC are late presenters with
repeated episode of OPC and prone for repeated expos-
ure to antifungal drugs though half of the patients had
reported to a single exposure with a mean time of 27
days which may be too low to note species shitting. In-
deed, three-forth of the patients with multiple Candida
colonization had reported recurrent episodes of OPC
and exposure to antifungal agents, which possibly sup-
port our hypothesis and the view that previous exposure
to antifungal agents as a risk factor for Candida species
shift. The high frequency (42%) of mixed colonization,
usually C. albicans with other Candida species in our
study is consistent with previous studies from HIV posi-
tive individuals [14,25] and patients with cancer [26].
The 28% isolation of non-albican Candida species from
patients with recurrent OPC and previous exposure to
antifungal agents in the current study clearly shows the
pathogenic role of non-albicans species in clinical OPC
among HIV/AIDS patients as it has been previously
reported [25]. The presence of pseudomembraneous
candidiasis and isolation of Candida species in 11 early
presenting AIDS patients suggest that some other indi-
vidual host characteristics must play a major role in de-
termining the status of yeast carrier, which, eventually,
could lead to a symptomatic infection. On top of this the
low diversity of Candida species isolated from apparently
health HIV negative individuals support our hypothesis
and the view that previous exposure to antifungal agents
as a risk factor for Candida species shift.
The prevalence of clinical drug resistance has increased
in recent decades with the greater use and abuse of effica-
cious antimicrobial agents. This has been a significant
problem for bacterial pathogens, where resistance to mul-
tiple antibiotics severely limits therapeutic options. In
deed, antimicrobial resistance is not restricted to bacteria,
however, and in the 1990s fluconazole treatment failure
emerged due to the development of resistance by the fun-
gal pathogen C. albicans [6]. Antifungal resistance is par-
ticularly problematic as initial diagnosis of systemic fungal
infection can be delayed with the availability of limited
antifungal agents and currently represents a great clinical
challenge. Given the difficulties observed in the treatment
of fungal infections in some groups of patients, identifica-
tion of the susceptibility profile of the yeast isolate are
recommended which could act as a guide in the selection
and control of antifungal therapy [27]. In the current
study, 32% (29/90) of the Candida isolates were found to
Table 4 Multi drug resistance profile of Candida isolates from oral cavity of AIDS patients, northwest Ethiopia, 2008
Candida species Pattern Antifungal agents MDR
Fluconazole Ketoconazole Itraconazole Amphotericin B 5-Fluorocytosine Micafungin
C. albicans (25) S 20 (80) 22 (88) 20 (80) 24 (96) 24 (96) 24 (96) -
SDD 1 (4) - 3 (12) - - - -
R 4 (16) 3 (12) 2 (8) 1 (4) 1 (4) 1 (4) 3 (12)
C. glabrata (25) S 22 (88) 24 (96) 22 (88) 25 (100) 24 (96) 25 (100) -
SDD 1 (4) - 2 (8) - - - -
R 3 (12) 1 (4) 1 (4) - 1 (4) - 2 (8)
C. tropicalis (25) S 23 (92) 24 (96) 22 (88) 25 (100) 24 (96) 25 (100) -
SDD - - 2 (8) - - - -
R 2 (8) 1 (4) 1 (4) - 1 (4) - 2 (8)
C. krusei (10) S 8 (80) 9 (9) 9 (90) 10 (100) 10 (100) 10 (100) -
SDD 1 (10) - 1 (10) - - - -
R 1 (10) 1 (10) - - - - 1 (10)
Other Candida spp* (5) S 4 (80) 4 (80) 4 (80) - - - -
SDD - - 1 (20) - - - -
R 1 (20) 1 (20) - - - - 1 (20)
Keys: S-Susceptible; SDD-Susceptible dose dependent; R-Resistant; MDR-Multi drug resistance; *: Unidentified Candida species.
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be resistant to one or more antifungal agents tested which
is relatively high compared with other similar studies from
Africa [8,23,24] and the rest of the world [21,28]. Of the
29 Candida isolates which were resistant to one or more
antifungal agents, more than half of the isolates (58%)
were non albicans which may reflect the intrinsic less sus-
ceptibility of some non albicans (C. glabrata and C. krusei)
to some antifungal agents like fluconazole [14]. This might
be also a reflection of the inappropriate use of antifungal
in the setting as the case has been observed in antibiotics
use [29]. The finding of one fluconazole resistant and one
SDD C. krusei (which is known intrinsically resistant flu-
conazole) among 10 isolates may indicate the influence of
region-species-difference on intrinsic resistance to azole
in particular and needs further investigation. Irrespective
of the Candida species identified, 12.2% (11/90), 7.7%
(7/90) and 4.7% (4) of the isolates were resistant to fluco-
nazole, ketoconazole and itraconazole, respectively most
of which are isolated from patients with recurrent epi-
sodes of OPC and previous exposure to antifungal. This
indicates the presence of induction of reduced susceptibil-
ity to azoles among these groups of patients and augments
on the existing data that documented patients with more
recurrent episodes of OPC and repeated exposure to anti-
fungal therapies posed a great risk of reduced susceptibil-
ity to azole antifungal agents [8,30,31]. Indeed, it has been
documented that Candida resistance to azole compounds
has frequently been attributed to a selective pressure
caused by antifungal agents and azole cumulative doses
due to exposure to several courses of short- or long-term
suppressive therapies in patients with OPC [32].
The frequency of fluconazole resistance in literatures
varies from country to country and from setting to setting
in the same country. Several recent studies have reported
fluconazole resistance in Candida strains isolated from
HIV-infected patients with OPC [8,12,22,23,32,33]. In the
current study taking those patients with SDD, 15% of the
isolates had resistance to fluconazole which is relatively
high compared with similar previous studies. This could
be associated with the accessibility of the drug with free of
charge with the scale up of HAART in 2005 in the country
and the frequent usage of the drugs as drug of choice in
the settings. The susceptibility profile of the sensitive
Candida organisms (irrespective of the species) showed
activity at relatively high MICs (mean MIC 7.32 μg/ml).
Our study showed that, C. albicans generate relatively low
fluconazole MICs (6.1 μg/ml) compared with C. glabrata
(8.04 μg/ml) which has been reported to often generate
considerably high fluconazole MICs [34]. This fluconazole
MIC value is by far too high compared with a recent study
from Brazil where 90% of the isolated Candida species were
inhibited by fluconazole at a concentration of 2.0 μg/ml
[35]. The frequency of resistance to ketoconazole and itra-
conazole was relatively lower and found to be 6.6% and
4.4%, respectively with MIC between 0.03–4.0 μg/ml and
0.5–8 μg/ml for ketoconzole and itraconazole, respectively
which is comparable with other studies [8,28,35]. Interest-
ingly, we found low rate of resistance with relatively low
MIC value of 0.13 μg/ml for amphotericin B which in ag-
reement with recent findings that reported most isolates of
C. albicans were sensitive to amphotericin B [8,12,21,36]
despite over 50 years of use of polyene antifungal drugs
(amphotericin B) [21,36]. Our finding of concomitant re-
sistance between fluconazole and itraconazole in 5 patients
and fluconazole and ketoconzole in 2 patients agrees with
the review by Rogers [37] on data from a study of Candida
isolates in HIV-positive patients that indicates a high level
of cross-resistance to itraconazole in fluconazole-resistant
non albicans compared with C. albicans and non albicans
isolates. Thus, when fluconazole resistance in Candida
species is observed, it is generally considered preferable
not to use itraconazole or other member of azoles [37].
The absence of cross-resistance between the ‘azole’
class drugs and either the polyene (amphotericin B) or
echinocandins (micafungin) is in agreement with pub-
lished data by Rautemaa et al. who reported that most
isolates of C. albicans were sensitive to amphotericin B
[36] despite the use of polyene antifungal drugs for over
half century [38]. It is worse enough to note, a wide vari-
ation in MIC values of the isolates from AIDS patients
and HIV negative patients in the current study. A simi-
lar finding has been reported from Brazil [21]. Two
HIV-tuberculosis coinfected patients and on antituber-
culosis drugs for the past 2 months have reported repeat
episodes of OPC and frequent exposure to various azoles
and had clinical OPC for several months in spite of being
infected by a susceptible strain of C. albicans and C. tropi-
calis. Although it is difficult to explain, it could be due to
impaired drug absorption and drug interaction (rifampicin
and ‘azoles’) which reduces the antifungal effect [37].
Conclusions
HIV/AIDS patients are orally colonized by single or mul-
tiple albicans and non- albicans Candida species that are
frequently resistant to ‘azoles’ and rarely to amphotericin
B, 5-Fluorocytosine and micafungin. These could repre-
sent a serious therapeutic problem among AIDS patients
with significant public health importance and highlight
the need for national surveillance for examining Candida
epidemiology and resistance to antifungal drugs. More-
over, longitudinal studies to examine the predisposing
factors for non-albicans species colonization are also im-
portant. Producing updated information on local fungal
pathogens and their sensitivity patterns is a prime tool in
combating such problem. Since high rate of susceptibility
was seen for polyene (amphotericin B), fluorinated pyrimi-
dine analogue (5-Fluorocytosine) and echinocandins (mica-
fungin), these antifungal may be used for the immediate
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empirical therapy of OPC for patients with recurrent epi-
sodes of OPC and in areas where culture and sensitivity
testing is not available. However, the patients should be
monitored regularly because of the known toxic effects of
the drugs.
Limitations
Certainly, this study have some obvious limitations such
as lack of standardized procedure following CLSI protocol
(including the use of non synthetic medium for suscepti-
bility test and ATCC 102321 as quality control strains)
and a lack of complete identification. The in vitro suscep-
tibility of yeast to antifungal agents of drugs may depend
on several factors including the growth medium used for
the susceptibility testing because of possible interaction of
the antifungal agent with components of the medium
which may interfere with antifungal activity. Accordingly,
RPMI medium is recommended for susceptibility testing
of yeasts by CLSI methodology [19]. Nevertheless, it is
very difficult to carry out CLSI method in developing
countries like Ethiopia for various reasons. Thus, based on
previously published data [20,39,40] and our observation
we substituted RPMI by non synthetic medium-TSB for
in vitro susceptibility to antifungal agents. Although, com-
parative studies have not been documented, the use of
ATCC 10231 has been practiced and configured to pro-
duce results paralleling with the reference method and
this strain was used as a quality controls strains as previ-
ously described [41]. Thus. we believe that these modifica-
tions could not result significant influence on recovery of
the Candida species and susceptibility test results pre-
sented in this paper could be comparable with previous
findings although minor difference are inevitable.
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